Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression

Journal of Nephrology

Volumn 25, Issue 2, 2012, Pages 198-203

  Roccatello, Dario ^a   Rossi, Daniela ^a   Marletto, Fabio ^a   Naretto, Carla ^a   Sciascia, Savino ^a   Baldovino, Simone ^a   Piras, Doloretta ^a   Giachino, Osvaldo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Glomerulonephritis therapy; IgA nephropathy; Mycophenolate mofetil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CAPILLARY; CELL PROLIFERATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOMERULOSCLEROSIS; HEMATURIA; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MALE; MESANGIUM CELL; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES;

EID: 84863331196     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.8452     Document Type: Article

References (11)

1. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503-512.
2. Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009;5:132-42
3. Roccatello D, Ferro M, Cesano G, et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant. 2000;15:833-835.
4. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.
5. Cattran DC, Coppo R, Cook HT, et al; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534-545.
6. Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi (Taipei). 2002;82:796-801.
7. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebocontrolled randomized study. Kidney Int. 2004;65:1842-1849.
8. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139-2145.
9. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802-812.
10. Tang SCW, Tang AWC, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77:543-549.
11. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783-1790.